Verona Pharma (VRNA) said Wednesday that the US Food and Drug Administration has approved Ohtuvayre as maintenance treatment for adult patients with chronic obstructive pulmonary disease.
Ohtuvayre is delivered to the lungs through a standard jet nebulizer, the firm said. It expects to launch the inhaled product in Q3.
Price: 14.75, Change: +0.06, Percent Change: +0.41
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments